Navigation Links
ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
Date:8/7/2008

Positive Results to Date Drive Decision to Expand its Proprietary

Therapeutic Pipeline

ZURICH, Switzerland, Aug. 7 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that the company has raised an additional CHF 23M (USD 22M, EUR 14M) in an extended Series B venture round to expand its development pipeline. A global syndicate of current investors participated in this round including SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Bioventures, BioMedinvest and VI Partners.

This funding builds on the company's CHF 50M (USD 49M, EUR 31M) Series B round, which closed in August 2006 and has enabled the company to move its lead molecule, ESBA105, into clinical trials. ESBA105 is a single-chain antibody fragment directed against TNF-alpha and is developed in ophthalmic and additional inflammatory indications.

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, commented, "We are delighted to announce the expansion of our proprietary pipeline with this additional financing. This includes building broad franchises in ophthalmology, rheumatology and respiratory diseases for ESBA105 and additional antibody fragments. Since the announcement of the Series B financing in August 2006, ESBATech has made significant progress in R&D, including the demonstration in animal models that high concentrations of ESBA105 can be achieved in all segments of the eye with topical delivery via eye drops. Furthermore, we have advanced our anti-VEGF program to selection of a development candidate, ESBA903, a single-chain antibody that shows very high potency, stability and solubility, and will be developed for ophthalmic indications. Just like ESBA105, this antibody fragment will be delivered via eye drops and thus represents a true alternative to the current intra-vitreal injections of marketed anti-VEGF inhibitors."

Martin Gertsch, Chief Financ
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
2. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
3. Light Sciences Oncology Raises $40.1 Million in Series C Financing
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
6. EntreMed Raises $20 Million to Support Clinical Development Program
7. Globus Medical Raises $110 Million in Series E Financing Round
8. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
9. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
10. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
11. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... 15, 2014  In an unprecedented effort to curb the spread of ... other transport vehicles, an advanced and portable UV germicidal lamp manufactured ... first time. In order to prevent EMS paramedics ... West Palm Beach Fire Rescue is the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... Young Innovations, Inc. (NASDAQ: YDNT ) today announced ... 2012.  Sales for the first quarter of 2012 ... in the first quarter of 2011. Income from operations increased 5.3% ... million in the first quarter of 2011. Net income increased 5.6% ...
... April 23, 2012  This week COPAN launched videos ... The new videos were created for the Centers ... to be used in a web based course ... for healthcare providers.  The educational videos show proper ...
Cached Medicine Technology:Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 3Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 4COPAN Produces CDC/Joint Commission Educational Specimen Collection Videos 2
(Date:4/22/2014)... The Association for Molecular Pathology (AMP) released a ... Diagnostics on recommendations for a molecular diagnostics ... of education. The report was prepared by the ... the AMP Training and Education Committee. "Our goal ... future medical laboratory scientists appropriately in order to ...
(Date:4/22/2014)... have found a way to block abnormal cholesterol production, ... the main cause of heart attacks and strokes and ... develops when fat builds inside blood vessels over time ... their ability to feed oxygen-rich blood to the heart ... experiments, described April 7 in the journal Circulation ...
(Date:4/22/2014)... German . , ... their mode of action is complex: In low concentrations ... while at high concentrations they can cause "oxidative stress", ... redox signaling unfolds in single cells and organelles in ... jointly by the teams of LMU Professor Martin Kerschensteiner ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
(Date:4/22/2014)... all seem to know who we say is neurotic and ... unable to act but simply doesn,t want to., ... of nearly 4,000 college students in 19 countries has uncovered ... and moving forward with life. Turns out that when they ... don,t like it as much as non-neurotics. Therefore persuasive communications ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:Neurotics don't just avoid action: They dislike it 2
... HealthDay Reporter , WEDNESDAY, April 27 (HealthDay News) -- If ... to be more severe than having one at any other time ... the heart attack happens between 6 a.m. and noon, it is ... heart attack occurring in the afternoon or evening, the researchers added. ...
... quality of life (HRQOL) for U.S. adults with arthritis is ... and mental health are affected by arthritis, which poses a ... diagnosed continues to climb. Details of this study are now ... published by Wiley-Blackwell on behalf of the American College of ...
... heart attack are likely to be more seriously affected if the ... in Heart journal. Heart attacks that occur between ... area of dead tissue (infarct) caused by the attack, which is ... of the day., , It is well established that a person,s ...
... April 27 (HealthDay News) -- The growing number of people ... people are becoming caregivers, a responsibility that health experts warn ... can take various steps to protect their health, says Rebecca ... Center in Houston. To keep stress in check, for ...
... By Kathleen Doheny HealthDay Reporter , WEDNESDAY, ... been known to improve blood sugar control, often sending ... have long wondered exactly how that happens. Now, ... acids linked with insulin resistance decline dramatically in those ...
... , BOSTON--Like brainy bookworms unprepared for the rough and tumble ... attack tumors tend to fade away quickly when injected into ... technique that can cause such cells to survive in patients, ... the need of other, highly toxic treatments, a new study ...
Cached Medicine News:Health News:Morning Heart Attacks Cause More Damage, Study Finds 2Health News:Morning Heart Attacks Cause More Damage, Study Finds 3Health News:Adults with arthritis suffer with poorer health related quality of life 2Health News:Heart attacks are more serious if they occur at certain times of the day 2Health News:Alzheimer's Caregivers Need Care, Too 2Health News:New Clues to How Gastric Bypass Surgery Combats Diabetes 2Health News:New Clues to How Gastric Bypass Surgery Combats Diabetes 3Health News:New technique extends cancer-fighting cells' potency in melanoma patients 2Health News:New technique extends cancer-fighting cells' potency in melanoma patients 3Health News:New technique extends cancer-fighting cells' potency in melanoma patients 4
Standard Deflectable Catheters...
... Quadripolar Multilumen Shaft Fixed ... The Medtronic CardioRhythm ... for use in diagnostic ... is designed for recording ...
... H Steerable Catheter. Steerable atrial ... of designs and a unique ... 10 to 24 electrodes, regular ... and active tip electrodes, and ...
The Polaris-DX steerable diagnostic catheter is designed for comfort and ergonomic handling during mapping procedures....
Medicine Products: